289038-17-1

Basic information

• Product Name: 2-BROMO-4-FLUOROCINNAMIC ACID
• Synonyms: 2-Bromo-4-fluorocinnamic acid 98%;2-Bromo-4-fluorocinnamicacid98%;2-BROMO-4-FLUOROCINNAMIC ACID;RARECHEM AL BK 1088
• CAS NO: 289038-17-1
• Molecular Formula: C9H6BrFO2
• Molecular Weight: 245.05
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives;Acids & Esters;Bromine Compounds;Fluorine Compounds
• Mol File: 289038-17-1.mol

Chemical Properties

• Melting Point: 237-238°C
• Boiling Point: 332.8 °C at 760 mmHg
• Flash Point: 155.1 °C
• Appearance: /
• Density: 1.685 g/cm³
• Vapor Pressure: 5.67E-05mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-BROMO-4-FLUOROCINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-FLUOROCINNAMIC ACID(289038-17-1)
• EPA Substance Registry System: 2-BROMO-4-FLUOROCINNAMIC ACID(289038-17-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 289038-17-1(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
2-Bromo-4-Fluorocinnamic Acid is used as a reagent in various organic chemistry reactions and the creation of complex molecules. Its unique structure, featuring a bromine and fluorine atom, contributes to its utility in scientific research.
Used in Pharmaceutical Industry:
As a member of the cinnamic acid family, 2-Bromo-4-Fluorocinnamic Acid is used as a precursor in the synthesis of pharmaceutical compounds due to its antifungal, antiviral, and antioxidant properties.
Used in Chemical Synthesis:
2-Bromo-4-Fluorocinnamic Acid is employed as an intermediate in the synthesis of various chemical compounds, leveraging its reactivity and unique structural features for the development of new molecules with potential applications in various industries.

InChI:InChI=1/C9H6BrFO2/c10-8-5-7(11)3-1-6(8)2-4-9(12)13/h1-5H,(H,12,13)/b4-2+

Upstream product

• 141-82-2 malonic acid 
• 59142-68-6 2-bromo-4-fluorobenzaldehyde 

Downstream Products

• 1006-39-9 1-(2-bromo-4-fluorophenyl)ethanone 

Relevant articles and documents

Iron-catalyzed domino decarboxylation-oxidation of α,β-unsaturated carboxylic acids enabled aldehyde C-H methylation

A practical and general iron-catalyzed domino decarboxylation-oxidation of α,β-unsaturated carboxylic acids enabling aldehyde C-H methylation for the synthesis of methyl ketones has been developed. This mild, operationally simple method uses ambient air as the sole oxidant and tolerates sensitive functional groups for the late-stage functionalization of complex natural-product-derived and polyfunctionalized molecules.

1,4-Palladium Shift/C(sp3)-H Activation Strategy for the Remote Construction of Five-Membered Rings

1,n-Metal shift is an elegant alternative approach enabling the functionalization of remote C-H bonds from simple precursors. In this work, we report a novel and simple Pd0-catalyzed domino reaction involving 1,4-palladium shift and C(sp3)-H activation and leading to (fused) five-membered rings. This method allowed access to a broad range of valuable arylidene γ-lactams and indanones and was applied to the formal synthesis of (-)-pyrrolam.

Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents

Cinnamic acid and its derivatives are known for anti-tubercular activity. The present study reports the synthesis of cinnamic acid derivatives via bioisosteric replacement of terminal carboxylic acid with “oxadiazole”. A series of cinnamic acid derivatives (styryl oxadiazoles) were designed and synthesized in good yields by reaction of substituted cinnamic acids (2, 15a-15s) with amidoximes. The synthesized styryl oxadiazoles were evaluated in vitro for anti-tubercular activity against Mycobacterium tuberculosis (Mtb) H37Ra strain. The structure-activity relationship (SAR) study has identified several compounds with mixed anti-tubercular profiles. The compound 32 displayed potent anti-tubercular activity (IC50 = 0.045 μg/mL). Molecular docking studies on mycobacterial enoyl-ACP reductase enzyme corroborated well with the experimental findings providing a platform for structure based hit-to-lead development.